AstraZeneca Partners with Jacobio to Co-Develop and Commercialize SHP2 Inhibitors for Cancer Treatment

阿斯利康与Jacobio宣布合作共同开发和商业化用于癌症治疗的SHP2抑制剂，并启动联合疗法的临床试验。

重要性分析

This collaboration could unlock new treatment paradigms for advanced solid tumors by combining SHP2 and MEK inhibitors. Success in these trials may lead to more effective combination therapies, potentially addressing unmet needs in oncology and strengthening AstraZeneca's position in the precision medicine market.

值得关注

The trial will test the combination of Jacobio's SHP2 inhibitor (JAB-3312) and AstraZeneca's MEK inhibitor (selumetinib).

AstraZeneca and Jacobio are collaborating on a clinical trial for advanced solid tumors.

市场背景

此Partnership反映了UK市场健康科技与生物技术领域的更广泛趋势。

本周 0 条新信号 → 0% 较上周

浏览此频道

查看公司浏览最新信号

关键事实

公司AstraZeneca

频道健康科技与生物技术

地区UK

信号类型合作

核心要点

1AstraZeneca and Jacobio are collaborating on a clinical trial for advanced solid tumors.

2The trial will test the combination of Jacobio's SHP2 inhibitor (JAB-3312) and AstraZeneca's MEK inhibitor (selumetinib).

3The partnership includes a clinical trial collaboration and a supply agreement.

来源背景

AstraZeneca has entered into a clinical trial collaboration and supply agreement with Jacobio Pharma. The partnership aims to evaluate the combination of Jacobio's SHP2 inhibitor, JAB-3312, and AstraZeneca's MEK inhibitor, selumetinib, for treating patients with advanced solid tumors. This collaboration will explore the potential synergistic effects of targeting both the SHP2 and MEK pathways in cancer therapy.

阅读完整来源 →

频道背景

查看频道